SG10201903656RA - Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor - Google Patents
Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitorInfo
- Publication number
- SG10201903656RA SG10201903656RA SG10201903656RA SG10201903656RA SG10201903656RA SG 10201903656R A SG10201903656R A SG 10201903656RA SG 10201903656R A SG10201903656R A SG 10201903656RA SG 10201903656R A SG10201903656R A SG 10201903656RA SG 10201903656R A SG10201903656R A SG 10201903656RA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- converting enzyme
- enzyme inhibitor
- beta blocker
- angiotensin converting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
PHARMACEUTICAL COMPOSITION COMPRISING A BETA BLOCKER AND A CONVERTING ENZYME INHIBITOR Fixed pharmaceutical composition comprising a beta blocker, bisoprolol, and an angiotensin converting enzyme inhibitor, perindopril, and use of said composition in the treatment and 5 prevention of cardiovascular diseases and more especially arterial hypertension, stable coronary artery disease or chronic heart failure. Medicaments.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1460654A FR3027803B1 (en) | 2014-11-05 | 2014-11-05 | PHARMACEUTICAL COMPOSITION COMPRISING A BETABLOQUANT AND A CONVERSION ENZYME INHIBITOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201903656RA true SG10201903656RA (en) | 2019-05-30 |
Family
ID=52345359
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201703550SA SG11201703550SA (en) | 2014-11-05 | 2015-11-04 | Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor |
| SG10201903656RA SG10201903656RA (en) | 2014-11-05 | 2015-11-04 | Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201703550SA SG11201703550SA (en) | 2014-11-05 | 2015-11-04 | Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP3215130B1 (en) |
| CY (1) | CY1123322T1 (en) |
| DK (1) | DK3215130T3 (en) |
| EA (1) | EA032808B1 (en) |
| ES (1) | ES2811904T3 (en) |
| FR (1) | FR3027803B1 (en) |
| GE (1) | GEP20196989B (en) |
| HR (1) | HRP20201518T1 (en) |
| HU (1) | HUE051947T2 (en) |
| LT (1) | LT3215130T (en) |
| MA (1) | MA40915B1 (en) |
| MX (1) | MX2017005848A (en) |
| MY (1) | MY187357A (en) |
| PH (1) | PH12017500786B1 (en) |
| PL (1) | PL3215130T3 (en) |
| PT (1) | PT3215130T (en) |
| RS (1) | RS60657B1 (en) |
| RU (1) | RU2702362C2 (en) |
| SG (2) | SG11201703550SA (en) |
| SI (1) | SI3215130T1 (en) |
| TN (1) | TN2017000170A1 (en) |
| UA (1) | UA122131C2 (en) |
| WO (1) | WO2016071631A1 (en) |
| ZA (1) | ZA201703078B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3234743A1 (en) | 2021-10-20 | 2023-04-27 | Les Laboratoires Servier | Novel trimetazidine salts |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003092729A1 (en) | 2002-05-03 | 2003-11-13 | Hexal Ag | Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor |
| WO2007010501A2 (en) * | 2005-07-22 | 2007-01-25 | Ranbaxy Laboratories Limited | A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor |
| HU230877B1 (en) * | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stable pharmaceutical combination |
| EP2424509A4 (en) * | 2009-04-30 | 2012-11-07 | Reddys Lab Ltd Dr | Fixed dose drug combination formulations |
| EP2566472B1 (en) | 2010-05-06 | 2015-01-07 | Cal International Limited | A pharmaceutical composition comprising aspirin and bisoprolol |
-
2014
- 2014-11-05 FR FR1460654A patent/FR3027803B1/en active Active
-
2015
- 2015-11-03 MA MA40915A patent/MA40915B1/en unknown
- 2015-11-04 EP EP15807949.1A patent/EP3215130B1/en not_active Revoked
- 2015-11-04 SI SI201531387T patent/SI3215130T1/en unknown
- 2015-11-04 LT LTEP15807949.1T patent/LT3215130T/en unknown
- 2015-11-04 MX MX2017005848A patent/MX2017005848A/en active IP Right Grant
- 2015-11-04 PL PL15807949T patent/PL3215130T3/en unknown
- 2015-11-04 MY MYPI2017701538A patent/MY187357A/en unknown
- 2015-11-04 SG SG11201703550SA patent/SG11201703550SA/en unknown
- 2015-11-04 HU HUE15807949A patent/HUE051947T2/en unknown
- 2015-11-04 RU RU2017115341A patent/RU2702362C2/en active
- 2015-11-04 DK DK15807949.1T patent/DK3215130T3/en active
- 2015-11-04 EA EA201790772A patent/EA032808B1/en unknown
- 2015-11-04 TN TN2017000170A patent/TN2017000170A1/en unknown
- 2015-11-04 WO PCT/FR2015/052975 patent/WO2016071631A1/en active Application Filing
- 2015-11-04 PT PT158079491T patent/PT3215130T/en unknown
- 2015-11-04 RS RS20200954A patent/RS60657B1/en unknown
- 2015-11-04 GE GEAP201514507A patent/GEP20196989B/en unknown
- 2015-11-04 SG SG10201903656RA patent/SG10201903656RA/en unknown
- 2015-11-04 UA UAA201705309A patent/UA122131C2/en unknown
- 2015-11-04 ES ES15807949T patent/ES2811904T3/en active Active
-
2017
- 2017-04-27 PH PH12017500786A patent/PH12017500786B1/en unknown
- 2017-05-04 ZA ZA201703078A patent/ZA201703078B/en unknown
-
2020
- 2020-09-07 CY CY20201100839T patent/CY1123322T1/en unknown
- 2020-09-23 HR HRP20201518TT patent/HRP20201518T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3215130T (en) | 2020-08-26 |
| PH12017500786A1 (en) | 2017-10-02 |
| FR3027803A1 (en) | 2016-05-06 |
| SI3215130T1 (en) | 2020-11-30 |
| CY1123322T1 (en) | 2021-12-31 |
| FR3027803B1 (en) | 2018-02-09 |
| RU2702362C2 (en) | 2019-10-08 |
| DK3215130T3 (en) | 2020-09-21 |
| EA201790772A1 (en) | 2017-09-29 |
| HRP20201518T1 (en) | 2020-12-11 |
| UA122131C2 (en) | 2020-09-25 |
| MA40915B1 (en) | 2020-08-31 |
| PH12017500786B1 (en) | 2017-10-02 |
| RU2017115341A3 (en) | 2019-05-21 |
| GEP20196989B (en) | 2019-07-10 |
| SG11201703550SA (en) | 2017-06-29 |
| WO2016071631A1 (en) | 2016-05-12 |
| MY187357A (en) | 2021-09-22 |
| PL3215130T3 (en) | 2020-11-16 |
| TN2017000170A1 (en) | 2018-10-19 |
| LT3215130T (en) | 2020-08-25 |
| MX2017005848A (en) | 2017-06-27 |
| EP3215130A1 (en) | 2017-09-13 |
| EA032808B1 (en) | 2019-07-31 |
| EP3215130B1 (en) | 2020-07-08 |
| HUE051947T2 (en) | 2021-03-29 |
| RS60657B1 (en) | 2020-09-30 |
| RU2017115341A (en) | 2018-11-05 |
| ZA201703078B (en) | 2020-11-25 |
| ES2811904T3 (en) | 2021-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007989A (en) | Compositions and methods for treating pterygium. | |
| EP3346915A4 (en) | Systems, devices, components and methods for detecting the locations of sources of cardiac rhythm disorders in a patient's heart | |
| MX2020009780A (en) | Autotaxin inhibitor compounds. | |
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| MX2023000796A (en) | Pharmaceutical composition, methods for treating and uses thereof. | |
| PH12018500762A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| WO2015120372A3 (en) | Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases | |
| PH12017500563A1 (en) | Stabilized adrenomedullin derivatives and use thereof | |
| EP3843620A4 (en) | Self-calibrating, cuffless, and non-invasive blood pressure monitor | |
| WO2015179823A8 (en) | Lung localized inhibitors of alpha(v)beta 6 | |
| UA118474C2 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MD4763B1 (en) | Pharmaceutical composition | |
| SG10201903656RA (en) | Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor | |
| WO2016144706A3 (en) | Autotaxin inhibitor compounds and uses thereof | |
| WO2016144704A3 (en) | Heterocyclic autotaxin inhibitor compounds | |
| GB2549031A (en) | Methods and drug therapies for patency of occluded blood vessels following angioplasty | |
| PH12020500295A1 (en) | Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same | |
| WO2016126572A3 (en) | Glucosylceramide synthase inhibitors and therapeutic methods using the same | |
| TN2018000344A1 (en) | Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| EA201892048A1 (en) | PHARMACEUTICAL COMPOSITION, CONTAINING EMAGAGLIFLOZIN, AND ITS APPLICATIONS | |
| TH1601003484A (en) | Isochromine derivatives as a phosphoinoxide 3-kinase inhibitor | |
| MX2018004295A (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof. | |
| TH1501007280A (en) | Oral formulation for the treatment of heart and circulatory diseases. (Cardiovascular Diseases) | |
| MX2014015781A (en) | Use of a1d-adrenergic antagonist, bmy-7378, for the treatment of prevention and reversal of the vascular hypertrophy in the arterial hypertension. |